PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Rang in aandelen #1443
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aandeelprijs
$37.68
Marktkapitalisatie
$15.58B
Verandering (1 dag)
2.60%
Verandering (1 jaar)
147.72%
Land
TW
Handel PharmaEssentia Corporation (6446)

Categorie

Healthcare
Aandelsplitsingen voor PharmaEssentia Corporation (6446)
Het aandeel PharmaEssentia Corporation (symbool: 6446) heeft in totaal 2 splitsingen ondergaan.
De meest recente splitsing vond plaats op Jul 09, 2026.
Eén aandeel 6446 dat vóór Sep 11, 2025 werd gekocht, staat nu gelijk aan 1.229881 aandelen 6446.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
2026-07-09 1109:1000 x1.109 x1.229881
2025-09-11 1109:1000 x1.109 x1.109
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten